Dalton Smart
Directeur Général chez HARPOON THERAPEUTICS, INC.
Fortune : 548 186 $ au 30/06/2024
Profil
Dalton E.
Smart currently works at Harpoon Therapeutics, Inc., as Chief Executive Officer, Acceleron Pharma, Inc., as President & Director, ArQule, Inc., as President & Director, Merck & Co., Inc., as Senior Vice President-Finance & Global Controller from 2023, and Junior Achievement of New Jersey, Inc., as Central Board Member.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
MERCK & CO., INC.
0,00% | 04/05/2024 | 4 428 ( 0,00% ) | 548 186 $ | 30/06/2024 |
Postes actifs de Dalton Smart
| Sociétés | Poste | Début |
|---|---|---|
| MERCK & CO., INC. | Comptroller/Controller/Auditor | 04/12/2023 |
| HARPOON THERAPEUTICS, INC. | Directeur Général | - |
| ACCELERON PHARMA INC. | President | - |
| ARQULE, INC. | President | - |
| Junior Achievement of New Jersey, Inc. | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
| Junior Achievement of New Jersey, Inc. | |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis on June 13, 2003 and is headquartered in Rahway, NJ. | Health Technology |
ArQule, Inc.
 ArQule, Inc. Pharmaceuticals: MajorHealth Technology ArQule, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company was founded in 1993 and is headquartered in Burlington, MA. | Health Technology |
